John J. Miller

2 weeks ago | psychiatrictimes.com | John J. Miller

According to a new study published in BMC Psychiatry, only 4.9% of patients who were prescribed antipsychotics for their psychiatric illness and had evidence of tardive dyskinesia (TD) had TD recorded properly in their electronic health records, supporting the idea that TD is often underreported and misdiagnosed and, therefore, not treated appropriately.1Yet, TD is a well-established adverse effect of antipsychotic medications and is often irreversible.

3 weeks ago | enjoyer.com | John J. Miller |John Miller

Benzonia — Bruce Catton was once asked how he could describe Civil War battles with such freshness, accuracy, and power. “I don’t know,” replied Catton. “Maybe I was there.”He wasn’t, of course: Catton was born more than three decades after the War Between the States. Yet this son of Northern Michigan grew up around a handful of veterans who enjoyed telling tales from the conflict.

1 month ago | psychiatrictimes.com | John J. Miller |Jonathan Meyer

TALKING WITH TITANS OF PSYCHOPHARMACOLOGYAt the 2025 American Psychiatric Association (APA) Annual Meeting, Psychiatric Times' Editor in Chief, John J. Miller, MD, sat down with leaders in psychopharmacology to discuss the topics they find most important. Jonathan M. Meyer, MD, DFAPA, presented on lithium, one of the strongest tools in psychiatry, expanding on our understanding of its mechanisms. How can we develop antidepressant drugs to enhance benefits and minimize adverse events?

1 month ago | psychiatrictimes.com | John J. Miller |Roger S. McIntyre

TALKING WITH TITANS OF PSYCHOPHARMACOLOGYAt the 2025 American Psychiatric Association (APA) Annual Meeting, Psychiatric Times' Editor in Chief, John J. Miller, MD, sat down with leaders in psychopharmacology to discuss the topics they find most important. Roger S. McIntyre, MD, FRCPC, has spent several decades dedicated to understanding the impact of insulin and metabolism on the brain.1 "A lightbulb moment for me happened while seeing patients.

1 month ago | psychiatrictimes.com | John J. Miller |John H Krystal

TALKING WITH TITANS OF PSYCHOPHARMACOLOGYAt the 2025 American Psychiatric Association (APA) Annual Meeting, Psychiatric Times' Editor in Chief, John J. Miller, MD, sat down with leaders in psychopharmacology to discuss the topics they find most important. John H. Krystal, MD, is best known for leading the discovery of ketamine's rapid antidepressant effects.1,2 He shared his latest insights on NMDA glutamate receptors and ketamine with Miller.